Investors

Investors 2017-11-02T11:57:23+00:00

Dimerix is discovering and developing important new drug therapies for major unmet medical needs identified using our proprietary cell-based drug discovery platform.

At the same time, our transformative drug discovery technology, known as Receptor-HIT, provides Dimerix with ongoing revenues from global industry partners seeking to improve their own programs.

Our vision is to positively improve human health through the creation of new treatments for major unmet medical needs.

Latest ASX Announcements

Recorded interview with CEO and rights issue reminder

The Dimerix Limited (ASX: DXB) Entitlement Offer or ‘Rights Issue’ to raise $5.5 million is due to close this Friday, 19 January 2018 at 7:00pm AEDT (Sydney time). Funds raised are important for the commercialisation of DMX-200 [...]

DMX-200 Dosage Optimisation Study Successfully Completed in Preparation for Phase 2b trial

Dimerix Limited announces top-line results from a recent pharmacokinetic (PK) study of an extended release tablet formulation for their DMX-200 program targeting Chronic Kidney Disease (CKD). The study found a newly formulated extended release tablet [...]

BIO-Europe 2017 interview with CEO Kathy Harrison on Phase II data

CEO Kathy Harrison discusses the exciting data from the Dimerix Phase 2a study in patients with Chronic Kidney Disease (CKD) in this interview from Bio-Europe 2017, Berlin, November 2017.  

Dimerix and Proteomics partner to improve treatment of Chronic Kidney Disease

MELBOURNE, Australia, 14 December 2017: Dimerix Limited (ASX: DXB), a clinical stage biotechnology company is pleased to announce that it has partnered with a leader in predictive diagnostics, Proteomics International (ASX:PIQ), to improve the treatment [...]

Read More

Media Coverage

PharmaVentures Interview with Kathy Harrison

Last November, Adrian Dawkes of PharmaVentures interviewed Kathy Harrison, CEO of Dimerix. Kathy discusses the companies focus on developing new therapeutic treatments identified using its proprietary drug discovery platform, Receptor-Heteromer Investigation Technology (HIT), and the [...]

Recorded interview with CEO and rights issue reminder

The Dimerix Limited (ASX: DXB) Entitlement Offer or ‘Rights Issue’ to raise $5.5 million is due to close this Friday, 19 January 2018 at 7:00pm AEDT (Sydney time). Funds raised are important for the commercialisation of DMX-200 [...]

DMX-200 Dosage Optimisation Study Successfully Completed in Preparation for Phase 2b trial

Dimerix Limited announces top-line results from a recent pharmacokinetic (PK) study of an extended release tablet formulation for their DMX-200 program targeting Chronic Kidney Disease (CKD). The study found a newly formulated extended release tablet [...]

BIO-Europe 2017 interview with CEO Kathy Harrison on Phase II data

CEO Kathy Harrison discusses the exciting data from the Dimerix Phase 2a study in patients with Chronic Kidney Disease (CKD) in this interview from Bio-Europe 2017, Berlin, November 2017.  

Read More

Analyst Reports

Baker Young DXB Flash Note November 2017

Read this here. 

Bioshares November 2017

View their report here. 

ASX Announcements – Baker Young Initiates Coverage of DXB

Baker Young Stockbrokers have initiated coverage of Dimerix Limited. The research report is available here: BY-DXB Research Report - Oct - Initiation of Coverage - BUY.

Video: NDF Research interview on Phase 2a results

In the interview, Kathy Harrison and Associate Professor David Packham, a Principal Investigator in the DMX-200 Phase 2a study and Director of Melbourne Renal Research Group, discusses Dimerix’s Phase 2a trial result of DMX-200 with [...]

Read More

Stock Quote

View stock price: ASX Stock Price

Email Alert

subscribe to news updates